<DOC>
	<DOCNO>NCT01715259</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic ( drug concentration change time ) profile abiraterone acetate 1000 mg administer single dose male participant impaired renal function compare individual normal renal function .</brief_summary>
	<brief_title>A Pharmacokinetic Study Abiraterone Acetate Male Participants With Impaired Renal Function Compared Individuals With Normal Renal Function</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) pharmacokinetics study evaluate single dose abiraterone acetate 1000 mg administer male participant end-stage renal disease compare matched-control ( match age body mass index ) participant normal renal function . There approximately 8 participant cohort ( group ) . The total study duration participant 36 day . Abiraterone acetate 1000 mg administer orally ( mouth ) single dose fasted state Day 1 . No food ingest 4 hour post-dose . Participants confine clinical research center day prior dose ( Day -1 ) Day 5 return clinic Days 8 , 15 , 22 follow . Serial pharmacokinetic sample collect safety monitor throughout study .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>All participant : Nonsmokers light smoker Body Mass Index 1838 kg/m2 inclusive Negative drug test , screen Day 1 , breathalyzer alcohol drug abuse Negative HIV antibody test screen Clinical laboratory value within protocoldefined parameter Agrees protocoldefined use effective contraception Participants may concurrent stable medical condition may include deem condition ( ) introduce additional risk factor interfere study objective procedure Patients renal impairment must additionally meet follow criterion : Must protocoldefined criterion endstage renal disease , moderate mild renal impairment Evidence stable renal impairment Control participants normal renal function must additionally meet follow criterion : Must good health All participant : Medical history malignancy except nonmelanoma skin cancer Participation investigational study drug trial receipt investigational study drug occur within 5 halflives drug 30 day prior dose abiraterone acetate , whichever long History alcoholism drug abuse within past 12 month Significant history clinical manifestation determine Investigator significant metabolic , allergic , dermatological , hepatic , hematological , pulmonary , cardiovascular , immunologic , neurological , psychiatric gastrointestinal condition , surgery resection would potentially alter absorption and/or excretion orally administer drug Clinically significant arrhythmias and/or history presence clinically significantly abnormal electrocardiogram Acute illness , especially active uncontrolled infection Not willing refrain strenuous exercise 48hours prior Day 1 period confinement clinical site Not willing abstain consuming : grapefruit caffeinecontaining food beverages 72 hour prior Day 1 alcoholcontaining food beverages 24 hour prior Day 1 Donation blood significant loss blood within 56 day prior Day 1 plan donation blood plasma screen 30 day Day 1 , inclusive The use prescription overthecounter ( OTC ) preparation know significantly inhibit induce liver enzyme involve drug metabolism within 30 day prior Day 1 Use prescription medications/products OTC , nonprescription preparation unrelated exist allowable stable medical condition within 5 halflives product 7 day prior dose abiraterone acetate , whichever longer Any acute chronic condition , opinion Investigator , would limit individual 's ability complete and/or participate clinical study Patients renal impairment meet follow criterion exclude study : Acute exacerbate renal disease , fluctuate rapidly deteriorate renal function indicate widely vary worsen sign renal impairment within 2 week Day 1 Hypertension ( systolic blood pressure [ BP ] &gt; 180 diastolic BP &gt; 100 ) Control participant normal renal function meet follow criterion exclude study : Hypertension ( systolic BP &gt; =160 diastolic BP &gt; =95 ) Any significant laboratory result consistent renal impairment</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Renal insufficiency</keyword>
	<keyword>Renal impairment</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>